Comparative Real-World Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients with Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study

Background

Dupilumab, mepolizumab, and benralizumab have each demonstrated efficacy in placebo-controlled trials for chronic obstructive pulmonary disease (COPD) with type 2 inflammation. However, no head-to-head trials or real-world comparative effectiveness studies have been reported. We aimed to compare the effectiveness of dupilumab, mepolizumab, and benralizumab in patients with COPD using propensity score-matched cohort analyses.